Document is current
Any future updates will be listed below
-
Authors
Stark, Jessica C. https://orcid.org/0000-0003-3828-5438
Gray, Melissa A.
Ibarlucea-Benitez, Itziar
Lustig, Marta
Bond, Annalise https://orcid.org/0000-0001-5300-8151
Cho, Brian
Govil, Ishika https://orcid.org/0000-0002-2865-4044
Luu, Tran
Priestley, Megan J. https://orcid.org/0000-0001-7805-2503
Veth, Tim S. https://orcid.org/0000-0002-2561-5437
Errington, Wesley J.
Bruncsics, Bence
Ribi, Mikaela K. https://orcid.org/0000-0001-6816-8326
Williams, Leo A. https://orcid.org/0009-0002-0136-7501
Sarkar, Casim A. https://orcid.org/0000-0002-0276-8203
Wisnovsky, Simon https://orcid.org/0000-0003-4010-4309
Riley, Nicholas M.
Morrissey, Meghan A. https://orcid.org/0000-0002-0531-4864
Valerius, Thomas https://orcid.org/0000-0001-9181-8067
Ravetch, Jeffrey V. https://orcid.org/0000-0003-2024-9041
Bertozzi, Carolyn R. https://orcid.org/0000-0003-4482-2754
- License Information
-
More Information
Article History
Received: 18 April 2024
Accepted: 25 September 2025
First Online: 16 December 2025
Change Date: 2 March 2026
Change Type: Update
Change Details: This paper was originally published under Creative Commons Attribution 4.0 International license, CC-BY-NC-ND, © The Author(s). It is now available under a Creative Commons Attribution 4.0 International license, CC-BY, © The Author(s). The error has been corrected in the online version of the article.
Competing interests
: Patent applications relating to antibody-decoy receptor chimeras have been filed by Stanford University (docket no. PCT/US2022/023166) and have been exclusively licensed to Valora Therapeutics. J.C.S. and C.R.B. are co-founders and scientific advisory board members of Valora Therapeutics. J.C.S. has received compensation for consulting and scientific advisory board membership from Rondo Therapeutics, AbTherx and Curie Bio, as well as speaker’s honoraria from Cullinan Therapeutics and Merck & Co. I.I.B. is currently employed by Regeneron Pharmaceuticals and holds stock in the company. C.R.B. is a co-founder and scientific advisory board member of GanNA Bio, Neuravid, Firefly Bio, Lycia Therapeutics, Palleon Pharmaceuticals, Enable Bioscience, Redwood Biosciences (a subsidiary of Catalent), OliLux Bio, Grace Science and InterVenn Biosciences. C.R.B. is a member of the Board of Directors of Xaira Therapeutics, Acepodia, Alnylam and OmniAb. All other authors declare no competing interests.
